With our team and associates we perform a large part of our due diligence on validation of the proof of concept as a beginning benchmark from which risk and returns can be more easily determined

Typically, a shorter investment period; 2-3 years to exit

The science is well understood and accordingly, 20/20 HCP’s managerial and operational support as lead investor is a critical component of program success

More specifically to the above bullet point, given the science orientation of the founders, we ensure the founders’ own advisory staff and third party investors all have the same clarity of purpose to guide the founder(s) through the required stages to achieve a successful exit. Additionally, a start-up will need to change directions a number of times due to both newly identified risks and opportunities. We quickly identify these inflection points and work with management to redirect the company accordingly

Exit valuation is understood and development risk is contained allowing for a more analytical approach to pre-money valuation…targeting returns in the a 3-7x range

Post proof of concept and with sufficient funding to complete the Verification and Verification studies (up through but before any regulatory approval process) we can immediately begin to engage big pharma to manage toward an exit. This provides us with additional trading information in support of finalizing an exit strategy (i.e.; sale, licensing, partnership with big pharma or a significant follow-on “up round” financing to proceed with regulatory approvals and/or commercialization as a stand-alone company